Hoechst Pakistan Limited (PSX:HPL)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
4,240.66
-21.88 (-0.51%)
At close: Feb 27, 2026
33.04%
Market Cap 40.90B
Revenue (ttm) 30.96B
Net Income (ttm) 2.90B
Shares Out 9.64M
EPS (ttm) 301.67
PE Ratio 14.06
Forward PE n/a
Dividend 240.00 (5.66%)
Ex-Dividend Date Apr 1, 2026
Volume 1,858
Average Volume 678
Open 4,300.00
Previous Close 4,262.54
Day's Range 4,221.90 - 4,300.00
52-Week Range 2,876.00 - 4,889.99
Beta 0.35
RSI 39.88
Earnings Date Feb 18, 2026

About Hoechst Pakistan

Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its allergy management, anti-diarrheals, antiemetic, antibiotic, cardiology, consumer healthcare, diabetes, and emergency care products under Flagyl, Clexane, Lantus, Amaryl, Claforan, Haemaccel, Secnidazole forte, Rulid, Targocid, Tavanic, Tarivid, Aventriax, Stemetil, Lasix, Winstor, Tritace, Cordarone, CoAprovel, Aprovel, CoPlavix, Selsun Blue, Apidra, Toujeo, Soliqu... [Read more]

Industry Pharmaceutical Preparations
Founded 1967
Employees 837
Stock Exchange Pakistan Stock Exchange
Ticker Symbol HPL
Full Company Profile

Financial Performance

In 2025, Hoechst Pakistan's revenue was 30.96 billion, an increase of 15.73% compared to the previous year's 26.75 billion. Earnings were 2.90 billion, an increase of 56.16%.

Financial Statements

News

There is no news available yet.